Gene expression markers for predicting response to chemotherapy

US7871769B2 · kind B2 · utility

Assignees

• Genomic Health, Inc. · US
• Instituto Nazionale Tumori · IT

Inventors

• Joffre B. Baker · Montara, US
• Steven Shak · Burlingame, US
• Luca Gianni · Milano, IT

Key dates

• Filing date: Apr 7, 2005
• Grant date: Jan 18, 2011
• Expiry date: Jun 29, 2028

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2474/20
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention provides sets of genes the expression of which is important in the prognosis of cancer. In particular, the invention provides gene expression information useful for predicting whether cancer patients are likely to have a beneficial treatment response to chemotherapy FHIT; MTA1; ErbB4; FUS; BBC3; IGF1R; CD9; TP53BP1; MUC1; IGFBP5; rhoC; RALBP1; STAT3; ERK1; SGCB; DHPS; MGMT; CRIP2; ErbB3; RAP1GDS1; CCND1; PRKCD; Hepsin; AK055699; ZNF38; SEMA3F; COL1A1; BAG1; AKT1; COL1A2; Wnt.5a; PTPD1; RAB6C; GSTM1, BCL2, ESR1; or the corresponding expression product, is determined, said report includes a prediction that said subject has a decreased likelihood of response to chemotherapy.